Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale

BACKGROUND: Preclinical studies, clinical trials, and reviews suggest increasing 3’,5’-cyclic adenosine monophosphate (cAMP) and 3’,5’-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer’s disease (AD). cAMP/protein kinase A (PKA) and cGMP/protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanders, Owen, Rajagopal, Lekshmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369141/
https://www.ncbi.nlm.nih.gov/pubmed/32715279
http://dx.doi.org/10.3233/ADR-200191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369141/
https://www.ncbi.nlm.nih.gov/pubmed/32715279
http://dx.doi.org/10.3233/ADR-200191

Ejemplares similares